Flavopiridol, fludarabine, and rituximab in mantle cell lymphoma and indolent B-cell lymphoproliferative disorders. - Wikidata - awgldk - TriplyDB

Flavopiridol, fludarabine, and rituximab in mantle cell lymphoma and indolent B-cell lymphoproliferative disorders.

Flavopiridol, fludarabine, and rituximab in mantle cell lymphoma and indolent B-cell lymphoproliferative disorders.

http://www.wikidata.org/entity/Q33627721

about

Cyclin-dependent kinase inhibitor therapy for hematologic malignancies The role of targeted treatment in mantle cell lymphoma: is transplant dead or alive?New molecular targets in mantle cell lymphoma Novel agents in mantle cell lymphoma Mantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agents Detailed Functional and Proteomic Characterization of Fludarabine Resistance in Mantle Cell Lymphoma Cells Treatment of synchronous mantle cell lymphoma and small lymphocytic lymphoma with bendamustine and rituximab.Phase I trial of bortezomib (PS-341; NSC 681239) and "nonhybrid" (bolus) infusion schedule of alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory indolent B-cell neoplasms.Flavopiridol can be safely administered using a pharmacologically derived schedule and demonstrates activity in relapsed and refractory non-Hodgkin's lymphoma.The history and future of targeting cyclin-dependent kinases in cancer therapy.Stimulation of chronic lymphocytic leukemia cells with CpG oligodeoxynucleotide gives consistent karyotypic results among laboratories: a CLL Research Consortium (CRC) Study Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era Molecular targeted approaches in mantle cell lymphoma.A phase II, single-arm, open-label, multicenter study to evaluate the efficacy and safety of P276-00, a cyclin-dependent kinase inhibitor, in patients with relapsed or refractory mantle cell lymphoma The cyclin-dependent kinase inhibitor flavopiridol potentiates doxorubicin efficacy in advanced sarcomas: preclinical investigations and results of a phase I dose-escalation clinical trial.Phase I trial of the combination of flavopiridol and imatinib mesylate in patients with Bcr-Abl+ hematological malignancies.Final results of EFC6663: a multicenter, international, phase 2 study of alvocidib for patients with fludarabine-refractory chronic lymphocytic leukemia.Loss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199)A dose-finding, pharmacokinetic and pharmacodynamic study of a novel schedule of flavopiridol in patients with advanced solid tumors.Initial therapy of mantle cell lymphoma Emerging drug profile: cyclin-dependent kinase inhibitors Gene mutations and actionable genetic lesions in mantle cell lymphoma.What is the best frontline therapy for patients with CLL and 17p deletion?Salvage therapy for relapsed chronic lymphocytic leukemia.A review of tumour lysis syndrome with targeted therapies and the role of rasburicase.The impact of multi-targeted cyclin-dependent kinase inhibition in breast cancer cells: clinical implications.Current status of targeted therapies for mantle cell lymphoma.Emerging agents for the treatment of mantle cell lymphoma.Current and emerging new treatment strategies for mantle cell lymphoma.Management of relapsed/refractory mantle cell lymphoma: a review of current therapeutic strategies.Transcription inhibition as a therapeutic target for cancer Genetic and molecular targets in lymphoma: implications for prognosis and treatment.Are we a step forward with targeted agents in resolving the enigma of mantle cell lymphoma?Novel agents in mantle cell lymphoma.Tumor lysis syndrome in the era of novel and targeted agents in patients with hematologic malignancies: a systematic review.Signaling proteins and pathways affected by flavonoids in leukemia cells.How to manage mantle cell lymphoma.Mechanism of the antitumoral activity of deferasirox, an iron chelation agent, on mantle cell lymphoma.Small interfering RNAs targeting cyclin D1 and cyclin D2 enhance the cytotoxicity of chemotherapeutic agents in mantle cell lymphoma cell lines.Cyclin D1 depletion induces DNA damage in mantle cell lymphoma lines.

P2860

Q24561485-D9181924-5C6A-4A25-A50F-7BD9CF92893E Q26772907-C28A73D7-2E54-4B35-B165-1BA3B4514BA2 Q26821766-176B2C55-1CD6-4DA0-AB9F-0FF6F971E1E9 Q27011763-016D2D48-F772-4A91-9894-37029AECC8D1 Q28075606-C384F3BA-04D5-4031-86E6-4675084CB620 Q28547322-0AFA5A00-E6E3-4A35-BE97-E5F4CE8CAD30 Q33394623-DD81EF29-4B12-4E44-88CF-3940666C865A Q33417803-2779D317-D63D-454C-854B-BBB605E8588C Q34114592-BBF37775-3716-4C2F-9D44-BAB5BD6601D3 Q34460347-474EEA7F-3A0B-4A00-B94B-EA3F742A6130 Q34479465-475FDFE4-7A16-40FC-BC7E-83E6E2B70EFF Q34568868-19E21D95-1CCD-44E5-AF6D-0296AF4496D6 Q35127368-C8C35156-B0B0-48BC-BBC1-E8F6C3E392DF Q35793148-0886A838-276B-4CB8-9DF0-2113A0EBFA1A Q35931388-A4DC55E3-7833-46CC-82C6-9B3DB0714A67 Q36002546-90B7AE01-8CA8-4B78-8489-2FDE95B9B85F Q36019515-B0437AD0-E1A7-4C93-9413-DCB6BE205BA5 Q36349985-922EDDA2-ED1B-4AD8-BB1A-CEA8A49276F9 Q36363971-A2A56106-A387-4DE1-AB8F-E104301BF1DA Q36612648-0AD5A567-CBF8-4965-9A23-3906022616CB Q37185372-796FE7F3-E69E-4B96-B663-E08FF724BA95 Q37629080-77351EE5-4108-4D75-ABD9-725C9BE84DA1 Q37820433-1B6DE674-F599-4509-A302-7ABB831C3B7E Q37865547-8E7E9675-C693-41D7-B33C-6C24C788BF52 Q37866341-A4898A1D-CD44-40FD-BFBB-FEF543C11392 Q37948079-CFAB90EC-1D23-41B6-A3E6-0DF32CC3EB84 Q37956405-5150FE9C-1A97-4B89-BCB7-8DB72A872C18 Q38055498-D44DA48B-B47D-4706-A047-F355623F8D76 Q38056761-3DBA0CDF-220F-4DB6-9524-629FBD9525C7 Q38122437-B7156955-9515-4577-8AB1-4ED6F99613D0 Q38161381-2CE19E21-BC7B-41E3-B86E-A72CCB902CEE Q38294626-7FB07EF5-5F64-4683-84EF-6E832BF3E4D1 Q38382492-ED75FC9C-6769-4CCB-8388-4BB7532E838C Q38516704-98A49E14-1B07-43DA-801F-99B7D107AFBF Q38693748-C22C5BB8-DE33-48E2-A738-4630BB8394AA Q38920087-AE5B133E-9E3A-4446-8427-7844F57984F0 Q39187610-7AFEBC13-8808-4A72-8774-8C064F3E2657 Q39269756-8FC20062-1C66-4900-A545-E57530CFD44E Q39509073-7AA0F633-C57F-41D9-8E0C-01630A7A031F Q47615901-E15CD2B9-905A-44C4-831E-7D13D4163A26

P2860

Flavopiridol, fludarabine, and rituximab in mantle cell lymphoma and indolent B-cell lymphoproliferative disorders.

http://www.wikidata.org/entity/Q33627721

description

2009 nî lūn-bûn

@nan

2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Flavopiridol, fludarabine, and ...... lymphoproliferative disorders.

@ast

Flavopiridol, fludarabine, and ...... lymphoproliferative disorders.

@en

type

label

Flavopiridol, fludarabine, and ...... lymphoproliferative disorders.

@ast

Flavopiridol, fludarabine, and ...... lymphoproliferative disorders.

@en

prefLabel

Flavopiridol, fludarabine, and ...... lymphoproliferative disorders.

@ast

Flavopiridol, fludarabine, and ...... lymphoproliferative disorders.

@en

P1433

Q33627721-36BBCE83-2F3B-4005-AA40-4DFC10463076

P1476

Q33627721-24B6BECB-E48B-424A-B2C5-C51E8A25F4C8

P2093

Q33627721-1CB5A28C-46FB-41E1-A575-7CEF4ADDB487

Q33627721-2AD24683-D40D-40EA-B1EB-7F43DBBDDBDE

Q33627721-2BBD1FBA-A1BF-4D0D-926D-927F0BB48EE0

Q33627721-4950E8C2-E54F-486D-AC41-FEE62914BCC1

Q33627721-5EB25272-E830-4F39-A89B-BD1EAF606BCA

Q33627721-783ECF76-C77E-4C10-984E-69CC32345DD6

Q33627721-7BB2A388-6BB9-4167-BCF8-34E59B7A9E93

Q33627721-A86AFB86-C137-41E4-8B7B-F3CB7CBF12E0

Q33627721-C3C60DF7-59C6-4652-A673-0B7340AAB56A

Q33627721-CE38C5DF-93F6-4CEF-BFD3-8EB9E7253F7E

P2860

Q33627721-05C6F501-F031-4400-BA92-9D3971015405

Q33627721-0A4277C0-12EB-4478-BBAB-BC76EEBC8688

Q33627721-12E6FAAF-0E6E-4756-9443-CB97D86D1AF2

Q33627721-1959CCFD-DD7F-484C-967A-6E8ED77751EC

Q33627721-1F6C16F1-CB1C-4C83-BD02-2746331FFC9A

Q33627721-2299429B-4FE8-4EF2-BE25-E2E135DF527F

Q33627721-2D13607C-7C06-458D-86D0-BFBED5CB31BD

Q33627721-3444BEE0-E0B9-4297-9C4D-1C0303202C52

Q33627721-4190EEBD-7AF2-49C3-821C-79C9AFA74583

Q33627721-60C551D0-F589-4D46-BEE9-426266575B44

P304

Q33627721-4EFDDA2B-1AFF-4F37-ADC4-63F5885C7412

P31

Q33627721-59C947E3-DE78-44DD-9FED-5A4BCD7B7E9F

P356

Q33627721-FA33F11E-461F-44E4-B944-D4FEF4968BBF

P407

Q33627721-E38CE6CC-7AF3-4078-A927-B2293B12C510

P433

Q33627721-A4B380E5-8E4B-45F2-AD99-521FA34E0C78

P478

Q33627721-C9A16FA5-6D6B-4D81-8D7E-4779DA7869A3

P50

Q33627721-04F390DE-4B01-46B1-9E76-AB2AA11DDBB4

Q33627721-0C51F399-AE35-4859-8543-26E459A78BC6

P577

Q33627721-14383C13-A053-4688-9EA0-248B20BE4805

P698

Q33627721-32CAC79F-2EB4-4834-A328-6542D690E776

P932

Q33627721-B2BE196B-C801-4FE8-A123-B0FD3B041B3B

P356

JCO.2009.24.1570

P1433

Journal of Clinical Oncology

P1476

Flavopiridol, fludarabine, and ...... lymphoproliferative disorders.

@en

P2093

Amy J Johnson

http://www.w3.org/2001/XMLSchema#string

Amy S Ruppert

http://www.w3.org/2001/XMLSchema#string

Diane Beth Fischer

http://www.w3.org/2001/XMLSchema#string

Eric H Kraut

http://www.w3.org/2001/XMLSchema#string

Kristie A Blum

http://www.w3.org/2001/XMLSchema#string

Larry J Schaaf

http://www.w3.org/2001/XMLSchema#string

Michael R Grever

http://www.w3.org/2001/XMLSchema#string

Mollie E Moran

http://www.w3.org/2001/XMLSchema#string

Pierluigi Porcu

http://www.w3.org/2001/XMLSchema#string

Robert A Baiocchi

http://www.w3.org/2001/XMLSchema#string

P2860

Genomic aberrations and survival in chronic lymphocytic leukemia

A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma

Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275

Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down-regulate antiapoptosis proteins in B-cell chronic lymphocytic leukemia.

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group.

Preclinical and clinical development of cyclin-dependent kinase modulators.

Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712).

National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment.

Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia.

The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle

P304

418-423

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2009.24.1570

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

28

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-12-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20008633

http://www.w3.org/2001/XMLSchema#string

P932

2815704

http://www.w3.org/2001/XMLSchema#string